Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
News|Articles|September 2, 2004
- Pharmaceutical Technology-09-02-2004
- Volume 28
- Issue 9
Design of an Aseptic Process Simulation
Author(s)Francis Roganti, Richard J. Boeh
The authors suggest a design strategy for an aseptic process simulation that focuses on the basic repeating unit of the process, establishing alert and action criteria for the unit itself, and using worst-case simulations to establish routine operational parameters for the manufacturing process.
Advertisement
Articles in this issue
about 22 years ago
In the Spotlight-September 2004about 22 years ago
Promoting Quality in Drug Manufacturingabout 22 years ago
Automation in a Digital, Webbed, and Wireless Ageabout 22 years ago
September 2004about 22 years ago
Early Development Still Driving CRO Performanceabout 22 years ago
Particulate-Free PalletsAdvertisement
Related to this article
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Vibha Jawa, PhD, chief scientific officer at EpiVax, discusses the limitations of current preclinical testing approaches and how new approach methodologies can strengthen drug development.
Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
AAPS PharmSci 360 2026: Roller-Compacted Formulations
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5